Skip to main content

Mediastinal radiation therapy for breast cancer in female patients is an independent risk factor for atrial fibrillation recurrence post-catheter ablation

Abstract

Background

The aim of this study was to assess the safety, efficacy, and predictors of outcomes for atrial fibrillation (AF) ablation in patients with a history of breast cancer.

Methods

Consecutive patients with a history of breast cancer undergoing AF ablation from January 2010 to December 2021 were propensity matched in a 1:1 ratio to patients without a history of any cancer. The primary outcome was procedural efficacy, defined by clinical AF recurrence and repeat catheter ablation. The secondary outcome was an assessment of safety looking at eight peri-procedural events.

Results

Our cohort was comprised of 82 female patients, 41 patients with a history of breast cancer (mean age, 74.6 ± 7.4 years), and 41 patients with no history of cancer (76.7 ± 8.1 years). Both groups had similar echocardiographic, baseline, and arrhythmia characteristics. Breast cancer patients were at an increased risk of AF recurrence post-ablation compared to non-cancer patients (OR 2.68, 95% CI 1.05–6.86, p = 0.04). Multivariate analysis found prior mediastinal radiotherapy (OR 4.79, 95% CI 1.34–17.1) and AF diagnosis to ablation time (OR 1.2, 95% CI 1.03–1.29) were both independent predictors of AF recurrence post-ablation.

Conclusion

Our study suggests that female patients with a history of breast cancer are at a higher risk of developing AF recurrence after catheter ablation. Multivariate analysis showed that patients with a history of prior mediastinal radiation therapy and AF diagnosis to time to ablation were both independent risk factors.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. Coughlin SS. Epidemiology of breast cancer in women. Adv Exp Med Biol. 2019;1152:9–29.

    CAS  Article  Google Scholar 

  2. Conen D, Wong JA, Sandhu RK, et al. Risk of malignant cancer among women with new-onset atrial fibrillation. JAMA Cardiol. 2016;1:389–96.

    Article  Google Scholar 

  3. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol. 2014;63:945–53.

    Article  Google Scholar 

  4. Wu N, Xu B, Xiang Y, et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis. Int J Cardiol. 2013;169:62–72.

    Article  Google Scholar 

  5. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74:104–32.

    Article  Google Scholar 

  6. Fradley MG, Beckie TM, Brown SA, et al. Recognition, prevention, and management of arrhythmias and autonomic disorders in cardio-oncology: a scientific statement from the American Heart Association. Circulation. 2021;144(3):e41–55.

  7. Giustozzi M, Ali H, Reboldi G, et al. Safety of catheter ablation of atrial fibrillation in cancer survivors. J Interv Card Electrophysiol. 2021;60:419–26.

  8. Schulman S, Kearon C, Subcommittee on control of anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–4.

    CAS  Article  Google Scholar 

  9. Wassertheil-Smoller S, McGinn AP, Martin L, Rodriguez BL, Stefanick ML, Perez M. The associations of atrial fibrillation with the risks of incident invasive breast and colorectal cancer. Am J Epidemiol. 2017;185:372–84.

    Article  Google Scholar 

  10. Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386:154–62.

    Article  Google Scholar 

  11. Chan DS, Bandera EV, Greenwood DC, Norat T. Circulating C-reactive protein and breast cancer risk-systematic literature review and meta-analysis of prospective cohort studies. Cancer Epidemiol Biomark Prev. 2015;24:1439–49.

    CAS  Article  Google Scholar 

  12. Yao C, Veleva T, Scott L Jr, et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. Circulation. 2018;138:2227–42.

    CAS  Article  Google Scholar 

  13. Ershaid N, Sharon Y, Doron H, et al. NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis. Nat Commun. 2019;10:4375.

    Article  Google Scholar 

  14. Chew DS, Black-Maier E, Loring Z, et al. Diagnosis-to-ablation time and recurrence of atrial fibrillation following catheter ablation: a systematic review and meta-analysis of observational studies. Circ Arrhythm Electrophysiol. 2020;13:e008128.

    Article  Google Scholar 

  15. Hussein AA, Saliba WI, Barakat A, et al. Radiofrequency ablation of persistent atrial fibrillation: diagnosis-to-ablation time, markers of pathways of atrial remodeling, and outcomes. Circ Arrhythm Electrophysiol. 2016;9:e003669.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christopher V. DeSimone.

Ethics declarations

Ethics approval

The study was approved by the institutional review board of Mayo Clinic (IRBe: 20–010812).

Consent to participate

Not applicable.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Haq, I.U., Akhiyat, N., Anan, A.R. et al. Mediastinal radiation therapy for breast cancer in female patients is an independent risk factor for atrial fibrillation recurrence post-catheter ablation. J Interv Card Electrophysiol (2022). https://doi.org/10.1007/s10840-022-01341-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10840-022-01341-7

Keywords

  • Atrial fibrillation
  • Pulmonary vein isolation
  • Breast cancer